Rebecca Robbins , The New York Times; Eli Lilly Reaches $1 Trillion in Value, Buoyed by Demand for Its Weight Loss Drugs
"Pharmaceuticals is a notoriously cyclical business. Companies buoyed by once-in-a-generation product lines flounder after their blockbuster drugs lose patent protection."
